Powerful Efficacy of GCSB-5 Treatment for Improving Fatigue and Motor Function in Multiple Sclerosis (MS): A Randomized Double Blind, Place-bo-Controlled Study
Multiple
Sclerosis (MS) is the most common disability in young adults that requires
early symptomatic treatment to prevent long-term disability. Among young
adults, MS is the most common central nerv-ous system (CNS) chronic
inflammatory illness that is characterized by demyelination in the CNS.
However, current disease-modifying treatments are not sufficiently effective
for preventing the variety of symptoms during the course of disease.
References
[1]
Barten,
L. J., Allington, D. R., Procacci, K. A., Rivey, M. P., Barten, L. J.,
Allington, D. R., ... & Rivey, M. P. (2010). New approaches in the
management of multiple sclerosis. Drug Design, De-velopment and Therapy, 4,
343.
[2]
Kim, E., Lovera, J., Schaben, L., Melara, J., Bourdette, D., &
Whitham, R. (2010). Novel method for measurement of fatigue in multiple
sclerosis: Real-Time Digital Fatigue Score. Journal of Re-habilitation Research
& Development, 47(5).
[3]
McDonald, S., & Clements, J. N. (2011).
Dalfampridine: a new agent for symptomatic manage-ment of multiple sclerosis.
American Journal of Health-System Pharmacy, 68(24).
[4]
National Multiple
Sclerosis Society (2014, May), Feys, P., Gijbels, D., Romberg, A., Santoyo, C.,
Gebara, B., de Noordhout, B. M., & Dalgas, U. (2012). Effect of time of day
on walking capacity and self-reported fatigue in persons with multiple
sclerosis: a multi-center trial. Multiple Sclerosis Journal, 18(3),
351-357. Kennedy, P., & Hutchinson,
C. B. Mobility in Multiple Sclerosis.
[5]
C.H. Polman, S.C. Reingold, G. Edan,
M. Filippi, H.P. Hartung, L. Kappos. (2005). Diagnostic criteria for multiple
sclerosis: 2005 revisions to the “McDonald Criteria”Ann Neurol, 58, pp. 840–846
6
[6]
Abdanipour, A., Tiraihi, T., Taheri, T., & Kazemi, H. (2013).
Microglial activation in rat experi-mental spinal cord injury model. Iranian
Biomedical Journal, 17(4), 214-20.
[7]
Kim, E., Cameron, M., Lovera, J.,
Schaben, L., Bourdette, D., & Whitham, R. (2011). American ginseng does not
improve fatigue in multiple sclerosis: a single center randomized double-blind
placebo-controlled crossover pilot study. Multiple Sclerosis Journal, 17(12),
1523-1526.
[8]
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mork,
S., & Bo, L. (1998). Axonal tran-section in the lesions of multiple
sclerosis. New England Journal of Medicine, 338(5), 278-285.
[9]
Kim, T. H.,
Yoon, S. J., Lee, W. C., Kim, J. K., Shin, J., Lee, S., & Lee, S. M.
(2011). Protective effect of GCSB-5, an herbal preparation, against peripheral
nerve injury in rats. Journal of Eth-nopharmacology, 136,2, 297-304.
[10]
Multiple Sclerosis Foundation (2009, July)
Retrieved from http://www.msfocus.org/Retrieved from
http://www.nationalmssociety.org/What-is-MS/Who-Gets-MS#section-0
[11]
Pender, M.
P., Csurhes, P. A., Houghten, R. A., McCombe, P. A., & Good, M. F. (1996).
A study of human T-cell lines generated from multiple sclerosis patients and
controls by stimulation with peptides of myelin basic protein. Journal of
neuroimmunology, 70(1), 65-74.
[12]
Snook, E. M., & Motl, R. W. (2009).
Effect of exercise training on walking mobility in multiple sclerosis: a
meta-analysis. Neurorehabilitation and neural repair, 23(2), 108-116.
[13]
Chung,
H. J., Lee, H. S., Shin, J. S., Lee, S. H., Park, B. M., Youn, Y. S., &
Lee, S. K. (2010). Modulation of acute and chronic inflammatory processes by a
traditional medicine preparation GCSB-5 both in vitro and in vivo animal
models. Journal of ethnopharmacology, 130,3), 450-459.
[14]
Ruck, T., Bittner,
S., Simon, O. J., Gobel, K., Wiendl, H., Schilling, M., & Meuth, S. G.
(2013). Long-term effects of dalfampridine in patients with multiple sclerosis.
Journal of the neurological sciences.
